The pharmaceutical industry faces mounting pressure to accelerate drug discovery while reducing costs and failure rates. Traditional
methods take 12-15 years and cost over $2.6 billion per drug, with a 90% failure rate in clinical trials. Artificial Intelligence (AI) is emerging as a game-changer, significantly improving target identification, lead discovery, clinical trial execution, and post-market surveillance.
Learn more in our latest Point Of View: Accelerating Drug Discovery with AI – A Strategic Roadmap
